PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31763809-4 2019 In such system, catalase acted as oxygen-self-supplier to catalyze the decomposition of tumor abundant H2O2 into O2, and the sustained release of RAP down-regulated HIF-1alpha, which collectively potentiated the PDT efficacy against tumor. Sirolimus 146-149 hypoxia inducible factor 1 subunit alpha Homo sapiens 165-175 33024904-9 2021 Significant differences between sirolimus and paclitaxel NPs in anti-proliferation effect under normoxia and hypoxia may due to the different inhibitory effects on HIF-1alpha expression and glycolysis. Sirolimus 32-41 hypoxia inducible factor 1 subunit alpha Homo sapiens 164-174 32692750-0 2020 Retraction: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF. Sirolimus 12-21 hypoxia inducible factor 1 subunit alpha Homo sapiens 89-94 33092063-2 2020 The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible factor (HIF)-1 pathway can be targeted by rapamycin and irinotecan, respectively. Sirolimus 117-126 hypoxia inducible factor 1 subunit alpha Homo sapiens 57-89 31383843-7 2019 The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation. Sirolimus 69-78 hypoxia inducible factor 1 subunit alpha Homo sapiens 132-141 31640284-5 2019 RESULTS: Rapamycin and cetuximab inhibited the mTOR/HIF-1alpha axis, and sensitized the SQ20B cell line to EGFR-inhibition. Sirolimus 9-18 hypoxia inducible factor 1 subunit alpha Homo sapiens 52-62 31383843-7 2019 The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation. Sirolimus 69-78 hypoxia inducible factor 1 subunit alpha Homo sapiens 132-136 31221957-6 2019 In this review, we focus on the molecular mechanisms regulating HIF-1alpha and aging-associated signaling proteins, such as sirtuins, AMP-activated protein kinase, mechanistic target of rapamycin complex 1, UNC-51-like kinase 1, and nuclear factor kappaB, and their roles in aging and aging-related diseases. Sirolimus 186-195 hypoxia inducible factor 1 subunit alpha Homo sapiens 64-74 28356986-9 2017 However, this hypoxia-induced increase in HIF-1alpha and CD44 protein and mRNA expression levels was inhibited by rapamycin. Sirolimus 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 30219159-13 2018 Furthermore, in vitro studies revealed that the inhibitory effect of rapamycin on the angiogenic ability of HUVECs and its significant inhibitory effects on the protein level of HIF-1alpha and the phosphorylation of proteins involved in the mTORC1 pathway, including mTOR, raptor and p70S6K (P < 0.05), were enhanced by cotreatment with SRT1720 and rapamycin (P < 0.05). Sirolimus 69-78 hypoxia inducible factor 1 subunit alpha Homo sapiens 178-188 29190547-7 2018 Treatment of H23 cells with mTOR siRNA or the mTOR inhibitor rapamycin abrogated LF-activated Akt-mTOR-Hif1-Foxo signaling and stemness-associated sonic hedgehog pathway, reversed Warburg metabolic switch and diminished invasion of H23 cells. Sirolimus 61-70 hypoxia inducible factor 1 subunit alpha Homo sapiens 103-107 28542038-10 2017 Western Blotting indicated that both doxorubicin and rapamycin inhibit hypoxia-induced accumulation of HIF-1alpha. Sirolimus 53-62 hypoxia inducible factor 1 subunit alpha Homo sapiens 103-113 28963126-7 2017 Rapamycin decreased basal and EGF stimulated HIF-1alpha and enhanced MAPK (ERK1/2) activation, while MAPK (ERK/12) inhibition downregulated HIF-1alpha expression and the phosphorylation of p70S6K. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 45-55 27044634-9 2016 The expression of HIF-1alpha protein and SNAIL mRNA could be inhibited gradually by rapamycin. Sirolimus 84-93 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-28 26937175-7 2016 Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis. Sirolimus 249-258 hypoxia inducible factor 1 subunit alpha Homo sapiens 208-217 26937175-7 2016 Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis. Sirolimus 249-258 hypoxia inducible factor 1 subunit alpha Homo sapiens 208-217 21567203-0 2012 Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1alpha induction. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 104-114 26620226-8 2016 The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins. Sirolimus 78-87 hypoxia inducible factor 1 subunit alpha Homo sapiens 149-159 24496328-4 2014 We found that rapamycin decreased HIF-1 and lactate levels in proliferating and senescent cells in vitro. Sirolimus 14-23 hypoxia inducible factor 1 subunit alpha Homo sapiens 34-39 23762265-4 2013 Forced expression of miR-99a or rapamycin treatment blocked insulin-induced PKM2 and HIF-1alpha expression, and glucose consumption and lactate production. Sirolimus 32-41 hypoxia inducible factor 1 subunit alpha Homo sapiens 85-95 23819061-4 2013 Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 227-238 22117756-6 2012 We evaluated the effect of the mTOR inhibitor rapamycin, which has been previously shown to block hypoxia-inducible factor (HIF) 1alpha. Sirolimus 46-55 hypoxia inducible factor 1 subunit alpha Homo sapiens 98-135 25988388-5 2015 The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1. Sirolimus 42-51 hypoxia inducible factor 1 subunit alpha Homo sapiens 19-29 25166211-3 2014 HIF-1alpha protein accumulation in normoxia was inhibited by rapamycin. Sirolimus 61-70 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 24018642-7 2014 Furthermore, sunitinib and rapamycin displayed synergistic activity against tube formation by human microvessel endothelial cells as well as outgrowth of endothelial tubes and microvessels both in vitro and in vivo, which is associated with down-regulation of VEGF secretion and HIF1alpha expression. Sirolimus 27-36 hypoxia inducible factor 1 subunit alpha Homo sapiens 279-288 23819061-4 2013 Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 64-75 21567203-5 2012 In addition, siRNA and ChIP assay were further applied to demonstrate the role of hypoxia-inducible factor 1 (HIF-1)alpha in regulating survivin expression regulation under hypoxia during rapamycin induced NSCLC cell apoptosis. Sirolimus 188-197 hypoxia inducible factor 1 subunit alpha Homo sapiens 110-121 21567203-9 2012 The results above collectively showed that rapamycin inhibits HIF-1alpha-induced survivin expression under hypoxia to induce NSCLC apoptosis. Sirolimus 43-52 hypoxia inducible factor 1 subunit alpha Homo sapiens 62-72 22900063-0 2012 Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 77-82 21521942-11 2011 The failure to limit mTOR-dependent induction of HIF-1 may contribute to age-related macular degeneration and diabetic retinopathy, suggesting rapamycin for prevention of these age-related diseases. Sirolimus 143-152 hypoxia inducible factor 1 subunit alpha Homo sapiens 49-54 21964931-9 2011 The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression. Sirolimus 49-58 hypoxia inducible factor 1 subunit alpha Homo sapiens 141-151 21252047-6 2011 In the presence of rapamycin, a specific mTOR inhibitor, leptin and PDGF were no longer able to activate mTOR, and expression of VEGF was reduced, whereas HIF-1alpha abundance was not affected. Sirolimus 19-28 hypoxia inducible factor 1 subunit alpha Homo sapiens 155-165 20139176-5 2010 The activation of HIF-1alpha by TNFalpha/IL-4 was countered by the phosphoinositol 3-kinase (PI3K) inhibitor LY-294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the MAPK pathway. Sirolimus 123-132 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-28 20554536-7 2010 In addition, combination treatment with HBC and various HIF-1 inhibitors, including suberoylanilide hydroxamic acid, rapamycin, and terpestacin, had greater anti-angiogenic activity than treatment with each single agent. Sirolimus 117-126 hypoxia inducible factor 1 subunit alpha Homo sapiens 56-61 20335389-4 2010 This up-regulation of HIF-1 alpha occurs under normoxic conditions and could be inhibited with wortmannin, Akt inhibitor, and rapamycin, consistent with the activation of a phosphoinositide-3 kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathway, respectively. Sirolimus 126-135 hypoxia inducible factor 1 subunit alpha Homo sapiens 22-33 19002496-9 2009 Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells. Sirolimus 32-41 hypoxia inducible factor 1 subunit alpha Homo sapiens 89-95 20156674-9 2010 The data indicate that in a relatively hypoxic environment HIF-1alpha may play a role in mediating the anti-cancer effect of rapamycin and cyclophosphamide may prevent the feedback activation of Akt by rapamycin. Sirolimus 125-134 hypoxia inducible factor 1 subunit alpha Homo sapiens 59-69 20156674-9 2010 The data indicate that in a relatively hypoxic environment HIF-1alpha may play a role in mediating the anti-cancer effect of rapamycin and cyclophosphamide may prevent the feedback activation of Akt by rapamycin. Sirolimus 202-211 hypoxia inducible factor 1 subunit alpha Homo sapiens 59-69 19789218-8 2009 CA-S6K1 overexpression reversed HIF-1alpha inhibition by rapamycin (a mammalian target of rapamycin/S6K1 inhibitor). Sirolimus 57-66 hypoxia inducible factor 1 subunit alpha Homo sapiens 32-42 19347904-6 2009 In contrast, treatment with rapamycin for 24 h reduced overall translation by approximately 45% and affected the translation of mRNAs with complex 5" UTRs, specifically VEGF and HIF1alpha. Sirolimus 28-37 hypoxia inducible factor 1 subunit alpha Homo sapiens 178-187 19002496-10 2009 Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia. Sirolimus 50-59 hypoxia inducible factor 1 subunit alpha Homo sapiens 89-95 19002496-11 2009 CONCLUSIONS: The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression. Sirolimus 45-54 hypoxia inducible factor 1 subunit alpha Homo sapiens 172-178 17645504-13 2008 In the following study, we indicated that hypoxia-inducible factor (HIF)-1alpha inhibitor, rapamycin, could possibly prevent VM and phenotype transformation of SKOV3ip, reflected by down-regulating expression of CD31 and Factor VIII. Sirolimus 91-100 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-79 18845636-2 2009 We report that the role of the phosphatidylinositol (PI)-3-kinase/AKT pathway in increasing HIF-1alpha protein in FSH-stimulated GCs extends beyond an increase in mammalian target of rapamycin-stimulated translation. Sirolimus 183-192 hypoxia inducible factor 1 subunit alpha Homo sapiens 92-102 19190131-11 2009 CONCLUSION: These results identify HIF-1alpha as a promising target and provide a rationale for clinical trials of low-dose irinotecan and rapamycin combination toward metastatic colon cancer. Sirolimus 139-148 hypoxia inducible factor 1 subunit alpha Homo sapiens 35-45 18781596-9 2009 Thus, activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway whereas HIF-1alpha activation obtained in high confluency is totally dependent on mTOR pathway as rapamycin totally impaired (i) HIF-1alpha stabilization and (ii) mRNA levels of CA9 and BNIP3, two HIF-target genes. Sirolimus 223-232 hypoxia inducible factor 1 subunit alpha Homo sapiens 20-30 18781596-9 2009 Thus, activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway whereas HIF-1alpha activation obtained in high confluency is totally dependent on mTOR pathway as rapamycin totally impaired (i) HIF-1alpha stabilization and (ii) mRNA levels of CA9 and BNIP3, two HIF-target genes. Sirolimus 223-232 hypoxia inducible factor 1 subunit alpha Homo sapiens 133-143 18781596-9 2009 Thus, activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway whereas HIF-1alpha activation obtained in high confluency is totally dependent on mTOR pathway as rapamycin totally impaired (i) HIF-1alpha stabilization and (ii) mRNA levels of CA9 and BNIP3, two HIF-target genes. Sirolimus 223-232 hypoxia inducible factor 1 subunit alpha Homo sapiens 133-143 18945681-6 2008 We report here that although there are clear differences in the sensitivity of HIF1 alpha and HIF2 alpha to rapamycin, both HIF1 alpha and HIF2 alpha expression is dependent on mTOR. Sirolimus 108-117 hypoxia inducible factor 1 subunit alpha Homo sapiens 79-89 18394010-8 2008 Rapamycin, while effective in decreasing HIF1alpha protein levels, did not affect HIF2alpha levels in either of the RCC cell lines. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 41-50 17968710-0 2007 Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 112-123 17968710-5 2007 Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 199-209 17968710-5 2007 Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway. Sirolimus 96-105 hypoxia inducible factor 1 subunit alpha Homo sapiens 199-209 17502379-4 2007 Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin. Sirolimus 237-246 hypoxia inducible factor 1 subunit alpha Homo sapiens 130-139 17190738-3 2006 Immunosuppressive agents should be used for preventing graft rejection, but of these, rapamycin and cyclosporine A have been reported to inhibit HIF-1. Sirolimus 86-95 hypoxia inducible factor 1 subunit alpha Homo sapiens 145-150 16849522-8 2006 Therefore, our results indicate that Akt can augment HIF-1alpha expression by increasing its translation under both normoxic and hypoxic conditions; however, the pathway we are investigating seems to be rapamycin insensitive and mTOR independent. Sirolimus 203-212 hypoxia inducible factor 1 subunit alpha Homo sapiens 53-63 16849522-10 2006 We did find that rapamycin could decrease HIF-1alpha expression when cells were cultured in low serum, but this seems to represent a different pathway. Sirolimus 17-26 hypoxia inducible factor 1 subunit alpha Homo sapiens 42-52 16627974-7 2006 HIF-1alpha activity was found to be required in Akt-induced melanocyte transformation and tumor growth and it was suppressed greatly by mTOR inhibition with rapamycin. Sirolimus 157-166 hypoxia inducible factor 1 subunit alpha Homo sapiens 0-10 16412252-12 2006 TSC1/TSC2 mutant cell lines administered Rapamycin blocked S6 phorphorylation and diminished the levels of HIF-1alpha to those observed in cell lines with wild type TSC1/TSC2. Sirolimus 41-50 hypoxia inducible factor 1 subunit alpha Homo sapiens 107-117 17483438-7 2007 Rapamycin failed to modulate levels of hypoxia-inducible factor 1alpha (HIF-1alpha) under normoxic conditions and modestly reduced hypoxia-driven increases in HIF-1alpha only in rhabdomyosarcoma cells. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 159-169 16515634-8 2006 The expression of HIF-1alpha was inhibited, and apoptotic index of tumor cell increased in rapamycin and rapamycin plus paclitaxel group. Sirolimus 91-100 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-28 16515634-8 2006 The expression of HIF-1alpha was inhibited, and apoptotic index of tumor cell increased in rapamycin and rapamycin plus paclitaxel group. Sirolimus 105-114 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-28 15944259-5 2005 In the present study, we showed that TCR engagement does not influence hypoxia-dependent stabilization but stimulates protein synthesis of HIF-1alpha, most possibly via PI3K/mammalian target of rapamycin system, and that expression of HIF-1alpha and its target genes is blocked by treatment with rapamycin. Sirolimus 194-203 hypoxia inducible factor 1 subunit alpha Homo sapiens 139-149 15050414-12 2004 Our results also indicated that the mTOR/FRAP inhibitor, rapamycin, inhibited 4-OHE2-induced HIF-1alpha and VEGF-A expression. Sirolimus 57-66 hypoxia inducible factor 1 subunit alpha Homo sapiens 93-103 12242281-5 2002 Pretreatment of PC-3 cells with the mTOR inhibitor, rapamycin, inhibited both the accumulation of HIF-1alpha and HIF-1-dependent transcription induced by hypoxia or CoCl(2). Sirolimus 52-61 hypoxia inducible factor 1 subunit alpha Homo sapiens 98-108 12242281-5 2002 Pretreatment of PC-3 cells with the mTOR inhibitor, rapamycin, inhibited both the accumulation of HIF-1alpha and HIF-1-dependent transcription induced by hypoxia or CoCl(2). Sirolimus 52-61 hypoxia inducible factor 1 subunit alpha Homo sapiens 98-103 12242281-6 2002 Transfection of these cells with wild-type mTOR enhanced HIF-1 activation by hypoxia or CoCl(2), while expression of a rapamycin-resistant mTOR mutant rendered both HIF-1alpha stabilization and HIF-1 transactivating function refractory to inhibition by rapamycin. Sirolimus 119-128 hypoxia inducible factor 1 subunit alpha Homo sapiens 165-175 12242281-6 2002 Transfection of these cells with wild-type mTOR enhanced HIF-1 activation by hypoxia or CoCl(2), while expression of a rapamycin-resistant mTOR mutant rendered both HIF-1alpha stabilization and HIF-1 transactivating function refractory to inhibition by rapamycin. Sirolimus 119-128 hypoxia inducible factor 1 subunit alpha Homo sapiens 165-170 16277894-7 2005 The levels of HIF-1alpha mRNA expression of SKOV3 and ES2 were 0.801 +/- 0.034 and 0.736 +/- 0.059 under hypoxia, which were significantly higher than under hypoxia added with sirolimus (0.025 +/- 0.007, 0.231 +/- 0.035; P < 0.01, P < 0.05), and those under no-hypoxia (0.010 +/- 0.004, 0.011 +/- 0.002; both P < 0.01). Sirolimus 176-185 hypoxia inducible factor 1 subunit alpha Homo sapiens 14-24 16277894-9 2005 Sirolimus can inhibit vasculogenic mimicry effectively by blocking HIF-1alpha at transcription level. Sirolimus 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 67-77 15347472-1 2004 OBJECTIVE: To investigate the inhibitory effect of the mammalian target of rapamycin (mTOR) inhibitor, sirolimus on expression of hypoxia-inducible factor (HIF)1alpha protein and growth of ovarian carcinoma in an athymic mouse xenogeneic transplant model of ovarian cancer. Sirolimus 103-112 hypoxia inducible factor 1 subunit alpha Homo sapiens 130-166 14982927-6 2004 FSH-stimulated HIF-1 activity is inhibited by the PI 3-kinase inhibitor LY294002, the Rheb inhibitor FTI-277 (farnesyltransferase inhibitor-277), and the mTOR inhibitor rapamycin. Sirolimus 169-178 hypoxia inducible factor 1 subunit alpha Homo sapiens 15-20 10749120-4 2000 LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis. Sirolimus 13-22 hypoxia inducible factor 1 subunit alpha Homo sapiens 143-148 10749120-4 2000 LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis. Sirolimus 13-22 hypoxia inducible factor 1 subunit alpha Homo sapiens 207-212